551
|
Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem 2010; 286:7966-7974. [PMID: 21156790 DOI: 10.1074/jbc.m110.178657] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Stargardt disease, also known as juvenile macular degeneration, occurs in approximately one in 10,000 people and results from genetic defects in the ABCA4 gene. The disease is characterized by premature accumulation of lipofuscin in the retinal pigment epithelium (RPE) of the eye and by vision loss. No cure or treatment is available. Although lipofuscin is considered a hallmark of Stargardt disease, its mechanism of formation and its role in disease pathogenesis are poorly understood. In this work we investigated the effects of long-term administration of deuterium-enriched vitamin A, C20-D(3)-vitamin A, on RPE lipofuscin deposition and eye function in a mouse model of Stargardt's disease. Results support the notion that lipofuscin forms partly as a result of the aberrant reactivity of vitamin A through the formation of vitamin A dimers, provide evidence that preventing vitamin A dimerization may slow disease related, retinal physiological changes and perhaps vision loss and suggest that administration of C20-D(3)-vitamin A may be a potential clinical strategy to ameliorate clinical symptoms resulting from ABCA4 genetic defects.
Collapse
Affiliation(s)
- Li Ma
- From the Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032
| | - Yardana Kaufman
- From the Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032
| | - Junhua Zhang
- From the Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032
| | - Ilyas Washington
- From the Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032.
| |
Collapse
|
552
|
Parmalee NL, Schubert C, Merriam JE, Allikmets K, Bird AC, Gillies MC, Peto T, Figueroa M, Friedlander M, Fruttiger M, Greenwood J, Moss SE, Smith LE, Toomes C, Inglehearn CF, Allikmets R. Analysis of candidate genes for macular telangiectasia type 2. Mol Vis 2010; 16:2718-26. [PMID: 21179236 PMCID: PMC3002960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2010] [Accepted: 12/09/2010] [Indexed: 11/29/2022] Open
Abstract
PURPOSE To find the gene(s) responsible for macular telangiectasia type 2 (MacTel) by a candidate-gene screening approach. METHODS Candidate genes were selected based on the following criteria: those known to cause or be associated with diseases with phenotypes similar to MacTel, genes with known function in the retinal vasculature or macular pigment transport, genes that emerged from expression microarray data from mouse models designed to mimic MacTel phenotype characteristics, and genes expressed in the retina that are also related to diabetes or hypertension, which have increased prevalence in MacTel patients. Probands from eight families with at least two affected individuals were screened by direct sequencing of 27 candidate genes. Identified nonsynonymous variants were analyzed to determine whether they co-segregate with the disease in families. Allele frequencies were determined by TaqMan analysis of the large MacTel and control cohorts. RESULTS We identified 23 nonsynonymous variants in 27 candidate genes in at least one proband. Of these, eight were known single nucleotide polymorphisms (SNPs) with allele frequencies of >0.05; these variants were excluded from further analyses. Three previously unidentified missense variants, three missense variants with reported disease association, and five rare variants were analyzed for segregation and/or allele frequencies. No variant fulfilled the criteria of being causal for MacTel. A missense mutation, p.Pro33Ser in frizzled homolog (Drosophila) 4 (FZD4), previously suggested as a disease-causing variant in familial exudative vitreoretinopathy, was determined to be a rare benign polymorphism. CONCLUSIONS We have ruled out the exons and flanking intronic regions in 27 candidate genes as harboring causal mutations for MacTel.
Collapse
Affiliation(s)
- Nancy L. Parmalee
- Department of Ophthalmology, Columbia University, New York, NY,Department of Genetics and Development, Columbia University, New York, NY
| | - Carl Schubert
- Department of Ophthalmology, Columbia University, New York, NY
| | | | - Kaija Allikmets
- Department of Ophthalmology, Columbia University, New York, NY
| | | | - Mark C. Gillies
- Save Sight Institute, Department of Clinical Ophthalmology and Eye Health, The University of Sydney, Sydney, Australia
| | | | | | - Martin Friedlander
- Department of Cell Biology, The Scripps Research Institute, La Jolla, CA
| | - Marcus Fruttiger
- Department of Cell Biology, University College London Institute of Ophthalmology, London, UK
| | - John Greenwood
- Department of Cell Biology, University College London Institute of Ophthalmology, London, UK
| | - Stephen E. Moss
- Department of Cell Biology, University College London Institute of Ophthalmology, London, UK
| | - Lois E.H. Smith
- Department of Ophthalmology, Harvard Medical School, Children's Hospital Boston, Boston, MA
| | - Carmel Toomes
- Section of Ophthalmology and Neuroscience, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK
| | - Chris F. Inglehearn
- Section of Ophthalmology and Neuroscience, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK
| | - Rando Allikmets
- Department of Ophthalmology, Columbia University, New York, NY,Department of Pathology and Cell Biology, Columbia University, New York, NY
| |
Collapse
|
553
|
Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010; 16:2598-604. [PMID: 21151600 PMCID: PMC3000236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Accepted: 12/02/2010] [Indexed: 10/31/2022] Open
Abstract
PURPOSE To determine whether gene polymorphisms of the major genetic risk factor for age-related macular susceptibility 2 (ARMS2 A69S) and the complement factor H Y402H influence the response to a variable-dosing treatment regimen with ranibizumab for age-related macular degeneration. METHODS This prospective cohort study included 90 patients (90 eyes) with exudative age related macular degeneration (AMD) treated with ranibizumab. Patients underwent a 1-year treatment as in the Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Mitchell et al.). Injections were administered monthly when a patient lost five letters on the Early Treatment Diabetic Retinopathy Study chart or gained 100 μm in central subfield retinal thickness (CSRT). Genotypes (rs10490924 and rs1061170) were analyzed using gene sequence analysis. Best-corrected visual acuity (BCVA) and CSRT values were compared between ARMS2 and complement factor H genotypes. Multiple regression analysis was used to assess the statistical significance. RESULTS Mean increase in visual acuity was 4.44±8.12 letters with a 103.63±94.7 µm decrease in CSRT. BCVA improvement was statistically significant in all genotype groups except in homozygous 69S in the AMRS2 gene. CSRT and BCVA changes were correlated (r=0.2521; 95% CI: 0.04746-0.4364, p=0.0165). Multiple regression analysis revealed a significant impact of 69S (p=0.015) on the change in BCVA. CONCLUSIONS Visual acuity did not improve during the study in patients homozygous for ARMS2 69S, despite a decrease in CSRT. Further investigation is needed to confirm our findings and understand the mechanisms involved.
Collapse
|
554
|
The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2010; 249:163-74. [PMID: 21127893 PMCID: PMC3042099 DOI: 10.1007/s00417-010-1568-6] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2010] [Revised: 10/25/2010] [Accepted: 10/29/2010] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Dysregulation of the complement system has been shown to play a major role in the pathogenesis of age-related macular degeneration (AMD). METHODS The current evidence from human studies derives from immunohistochemical and proteomic studies in donor eyes, genetic association studies, and studies of blood complement protein levels. These lines of evidence are corroborated by in vitro and animal studies. RESULTS In AMD donor eyes, detection of complement proteins in drusen suggested local inflammatory processes involving the complement system. Moreover, higher levels of complement proteins in the Bruch's membrane/choroid complex could be detected in AMD donor eyes compared to controls. A large number of independent genetic studies have consistently confirmed the association of AMD with risk or protective variants in genes coding for complement proteins, including complement factor H (CFH), CFH-related proteins 1 and 3, factor B/C2, C3 and factor I. Another set of independent studies detected increased levels of complement activation products in plasma of AMD patients, suggesting that AMD may be a systemic disease and the macula a vulnerable anatomic site of minimal resistance to complement activation. Genotype-phenotype correlations, including the impact of genetic variants on disease progression, gene-environment and pharmacogenetic interactions, have been investigated. There is evidence that complement gene variants may be associated with the progression from early to late forms of AMD, whereas they do not appear to play a significant role when late atrophic AMD has already developed. There are indications for an interaction between genetic variants and supplementation and dietary factors. Also, there is some evidence that variants in the CFH gene influence treatment effects in patients with neovascular AMD. CONCLUSIONS Such data suggest that the complement system may have a significant role for developing new prophylactic and therapeutic interventions in AMD. In fact, several compounds acting on the complement pathway are currently in clinical trials. Therapeutics that modulate the complement system need to balance inhibition with preservation of sufficient functional activity in order to maintain adequate immune responses and tissue homeostasis. Specifically, targeting the dysfunction appears more adequate than a global suppression of complement activation in chronic diseases such as AMD.
Collapse
|
555
|
Zeng J, Chen Y, Tong Z, Zhou X, Zhao C, Wang K, Hughes G, Kasuga D, Bedell M, Lee C, Ferreyra H, Kozak I, Haw W, Guan J, Shaw R, Stevenson W, Weishaar PD, Nelson MH, Tang L, Zhang K. Lack of association of CFD polymorphisms with advanced age-related macular degeneration. Mol Vis 2010; 16:2273-8. [PMID: 21139680 PMCID: PMC2994334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2010] [Accepted: 10/28/2010] [Indexed: 10/28/2022] Open
Abstract
PURPOSE Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide. Research has linked AMD susceptibility with dysregulation of the complement cascade. Typically, complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3) are associated with AMD. In this paper, we investigated the association between complement factor D (CFD), another factor of the complement system, and advanced AMD in a Caucasian population. METHODS Six single nucleotide polymorphisms (SNPs), rs1683564, rs35186399, rs1683563, rs3826945, rs34337649, and rs1651896, across the region covering CFD, were chosen for this study. One hundred and seventy-eight patients with advanced AMD and 161 age-matched normal controls were genotyped. Potential positive signals were further tested in another independent 445 advanced AMD patients and 190 controls. χ2 tests were performed to compare the allele frequencies between case and control groups. RESULTS None of the six SNPs of CFD was found to be significantly associated with advanced AMD in our study. CONCLUSIONS Our findings suggest that CFD may not play a major role in the genetic susceptibility to AMD because no association was found between the six SNPs analyzed in the CFD region and advanced AMD.
Collapse
Affiliation(s)
- Jiexi Zeng
- Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, China,Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA,Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT
| | - Yuhong Chen
- Department of Ophthalmology & Vision Science, Eye and ENT hospital, Shanghai Medical School, Fudan University, Shanghai, China,Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA,Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT
| | - Zongzhong Tong
- Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT
| | - Xinrong Zhou
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Chao Zhao
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA,Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT
| | - Kevin Wang
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Guy Hughes
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Daniel Kasuga
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Matthew Bedell
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Clara Lee
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Henry Ferreyra
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Igor Kozak
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Weldon Haw
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Jean Guan
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - Robert Shaw
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA
| | - William Stevenson
- Vitreo-Retinal Consultants & Surgeons, 530 North Lorraine, Wichita, KS
| | - Paul D. Weishaar
- Vitreo-Retinal Consultants & Surgeons, 530 North Lorraine, Wichita, KS
| | | | - Luosheng Tang
- Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, China
| | - Kang Zhang
- Institute for Genomic Medicine and Shiley Eye Center, University of California San Diego, San Diego, CA,Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
556
|
What has gene expression profiling taught us about glaucoma? Exp Eye Res 2010; 93:191-5. [PMID: 20946895 DOI: 10.1016/j.exer.2010.10.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Revised: 09/28/2010] [Accepted: 10/04/2010] [Indexed: 12/16/2022]
Abstract
The availability in recent years of new cellular and animal models, as well as advances in genomic and related technologies, have made possible important advances in our understanding of the cellular and molecular events that mediate retinal ganglion cell dysfunction and death in glaucoma. In this review, we briefly summarize the methodology and results of a number of genome-wide expression studies that have been performed to study the retina and optic nerve head in glaucoma.
Collapse
|
557
|
Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration? Retina 2010; 30:1333-49. [DOI: 10.1097/iae.0b013e3181e7976b] [Citation(s) in RCA: 281] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
558
|
Abstract
Age-related macular disease (AMD) accounts for more than 50% of blind registration in Western society. Patients with AMD are classified as having early disease, in which visual function is well preserved, or late disease, in which central vision is lost. Until recently, there was no therapy available by which the course of the disorder could be modified. Now, the most common form of late-stage AMD - choroidal neovascularization - responds to treatment with anti-VEGF therapies; although visual loss is modified in a portion of these cases, no therapeutic approach exists that alters the evolution from early to late disease. However, as discussed in this Review, research over the last few years has demonstrated several features of AMD that are likely to be amenable to treatment. Potential targets for treatment are described, and possible therapeutic approaches are discussed.
Collapse
Affiliation(s)
- Alan C Bird
- Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, London, UK.
| |
Collapse
|
559
|
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97. [PMID: 20720586 DOI: 10.1038/ni.1923] [Citation(s) in RCA: 2584] [Impact Index Per Article: 184.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Nearly a century after the significance of the human complement system was recognized, we have come to realize that its functions extend far beyond the elimination of microbes. Complement acts as a rapid and efficient immune surveillance system that has distinct effects on healthy and altered host cells and foreign intruders. By eliminating cellular debris and infectious microbes, orchestrating immune responses and sending 'danger' signals, complement contributes substantially to homeostasis, but it can also take action against healthy cells if not properly controlled. This review describes our updated view of the function, structure and dynamics of the complement network, highlights its interconnection with immunity at large and with other endogenous pathways, and illustrates its multiple roles in homeostasis and disease.
Collapse
Affiliation(s)
- Daniel Ricklin
- Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | |
Collapse
|
560
|
Liao JL, Yu J, Huang K, Hu J, Diemer T, Ma Z, Dvash T, Yang XJ, Travis GH, Williams DS, Bok D, Fan G. Molecular signature of primary retinal pigment epithelium and stem-cell-derived RPE cells. Hum Mol Genet 2010; 19:4229-38. [PMID: 20709808 DOI: 10.1093/hmg/ddq341] [Citation(s) in RCA: 153] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Age-related macular degeneration (AMD) is characterized by the loss or dysfunction of retinal pigment epithelium (RPE) and is the most common cause of vision loss among the elderly. Stem-cell-based strategies, using human embryonic stem cells (hESCs) or human-induced pluripotent stem cells (hiPSCs), may provide an abundant donor source for generating RPE cells in cell replacement therapies. Despite a significant amount of research on deriving functional RPE cells from various stem cell sources, it is still unclear whether stem-cell-derived RPE cells fully mimic primary RPE cells. In this report, we demonstrate that functional RPE cells can be derived from multiple lines of hESCs and hiPSCs with varying efficiencies. Stem-cell-derived RPE cells exhibit cobblestone-like morphology, transcripts, proteins and phagocytic function similar to human fetal RPE (fRPE) cells. In addition, we performed global gene expression profiling of stem-cell-derived RPE cells, native and cultured fRPE cells, undifferentiated hESCs and fibroblasts to determine the differentiation state of stem-cell-derived RPE cells. Our data indicate that hESC-derived RPE cells closely resemble human fRPE cells, whereas hiPSC-derived RPE cells are in a unique differentiation state. Furthermore, we identified a set of 87 signature genes that are unique to human fRPE and a majority of these signature genes are shared by stem-cell-derived RPE cells. These results establish a panel of molecular markers for evaluating the fidelity of human pluripotent stem cell to RPE conversion. This study contributes to our understanding of the utility of hESC/hiPSC-derived RPE in AMD therapy.
Collapse
Affiliation(s)
- Jo-Ling Liao
- Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
561
|
Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, Day AJ. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem 2010; 285:30192-202. [PMID: 20660596 DOI: 10.1074/jbc.m110.103986] [Citation(s) in RCA: 142] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Age-related macular degeneration (AMD) is the predominant cause of blindness in the industrialized world where destruction of the macula, i.e. the central region of the retina, results in loss of vision. AMD is preceded by the formation of deposits in the macula, which accumulate between the Bruch's membrane and the retinal pigment epithelium (RPE). These deposits are associated with complement-mediated inflammation and perturb retinal function. Recent genetic association studies have demonstrated that a common allele (402H) of the complement factor H (CFH) gene is a major risk factor for the development of AMD; CFH suppresses complement activation on host tissues where it is believed to bind via its interaction with polyanionic structures. We have shown previously that this coding change (Y402H; from a tyrosine to histidine residue) alters the binding of the CFH protein to sulfated polysaccharides. Here we demonstrate that the AMD-associated polymorphism profoundly affects CFH binding to sites within human macula. Notably, the AMD-associated 402H variant binds less well to heparan sulfate and dermatan sulfate glycosaminoglycans within Bruch's membrane when compared with the 402Y form; both allotypes exhibit a similar level of binding to the RPE. We propose that the impaired binding of the 402H variant to Bruch's membrane results in an overactivation of the complement pathway leading to local chronic inflammation and thus contributes directly to the development and/or progression of AMD. These studies therefore provide a putative disease mechanism and add weight to the genetic association studies that implicate the 402H allele as an important risk factor in AMD.
Collapse
Affiliation(s)
- Simon J Clark
- Faculty of Life Sciences, Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
562
|
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116:4395-403. [PMID: 20625009 DOI: 10.1182/blood-2010-01-261503] [Citation(s) in RCA: 137] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Beyond its role in immunity, complement mediates a wide range of functions in the context of morphogenetic or tissue remodeling processes. Angiogenesis is crucial during tissue remodeling in multiple pathologies; however, the knowledge about the regulation of neovascularization by the complement components is scarce. Here we studied the involvement of complement in pathological angiogenesis. Strikingly, we found that mice deficient in the central complement component C3 displayed increased neovascularization in the model of retinopathy of prematurity (ROP) and in the in vivo Matrigel plug assay. In addition, antibody-mediated blockade of C5, treatment with C5aR antagonist, or C5aR deficiency in mice resulted in enhanced pathological retina angiogenesis. While complement did not directly affect angiogenesis-related endothelial cell functions, we found that macrophages mediated the antiangiogenic activity of complement. In particular, C5a-stimulated macrophages were polarized toward an angiogenesis-inhibitory phenotype, including the up-regulated secretion of the antiangiogenic soluble vascular endothelial growth factor receptor-1. Consistently, macrophage depletion in vivo reversed the increased neovascularization associated with C3- or C5aR deficiency. Taken together, complement and in particular the C5a-C5aR axes are potent inhibitors of angiogenesis.
Collapse
|
563
|
Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, Rovin BH. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010; 19:1272-80. [PMID: 20605879 DOI: 10.1177/0961203310371154] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
To assess the relationship between serum C3 or C4 levels and lupus renal flare, C3 and C4 levels were measured bimonthly in 71 lupus nephritis patients for a mean of 35 months, during which time 70 renal flares were identified. Comparing baseline, pre-flare, and at-flare values indicated that neither C3 nor C4 levels decreased pre-flare, but both decreased on average significantly at flare. However, sensitivity/specificity for C3 (75%/71%) and C4 (48%/71%) were low. To account for other influencing factors, multiple regression was performed that included bimonthly values of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and genotype data on C3 (S/F), CRP (1846G > A), and the complement regulator factor H (Y402H). This analysis revealed that reduced levels of C4, but not C3, were independently associated with the two-month pre-flare period. Conversely, reduced levels of C3, but not C4, were independently associated with the flare visit. Significant pro-flare interactions included low C3 levels with the factor H 402HH-encoding genotype, and low CRP levels with the C3 F allele. Together these data suggest that C4 activation is critical for initiating renal flare while C3 activation is involved in the actual tissue damage, and that these effects are influenced by genetic variability in complement activation and regulation.
Collapse
|
564
|
Yuan X, Gu X, Crabb JS, Yue X, Shadrach K, Hollyfield JG, Crabb JW. Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics 2010; 9:1031-46. [PMID: 20177130 PMCID: PMC2877969 DOI: 10.1074/mcp.m900523-mcp200] [Citation(s) in RCA: 110] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2009] [Revised: 01/19/2010] [Indexed: 11/29/2022] Open
Abstract
A quantitative proteomics analysis of the macular Bruch membrane/choroid complex was pursued for insights into the molecular mechanisms of age-related macular degeneration (AMD). Protein in trephine samples from the macular region of 10 early/mid-stage dry AMD, six advanced dry AMD, eight wet AMD, and 25 normal control post-mortem eyes was analyzed by LC MS/MS iTRAQ (isobaric tags for relative and absolute quantitation) technology. A total of 901 proteins was quantified, including 556 proteins from > or =3 AMD samples. Most proteins differed little in amount between AMD and control samples and therefore reflect the proteome of normal macular tissues of average age 81. A total of 56 proteins were found to be elevated and 43 were found to be reduced in AMD tissues relative to controls. Analysis by category of disease progression revealed up to 16 proteins elevated or decreased in each category. About 60% of the elevated proteins are involved in immune response and host defense, including many complement proteins and damage-associated molecular pattern proteins such as alpha-defensins 1-3, protein S100s, crystallins, histones, and galectin-3. Four retinoid processing proteins were elevated only in early/mid-stage AMD, supporting a role for retinoids in AMD initiation. Proteins uniquely decreased in early/mid-stage AMD implicate hematologic malfunctions and weakened extracellular matrix integrity and cellular interactions. Galectin-3, a receptor for advanced glycation end products, was the most significantly elevated protein in advanced dry AMD, supporting a role for advanced glycation end products in dry AMD progression. The results endorse inflammatory processes in both early and advanced AMD pathology, implicate different pathways of progression to advanced dry and wet AMD, and provide a new database for hypothesis-driven and discovery-based studies of AMD.
Collapse
Affiliation(s)
- Xianglin Yuan
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| | - Xiaorong Gu
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| | - John S. Crabb
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| | - Xiuzhen Yue
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| | - Karen Shadrach
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| | - Joe G. Hollyfield
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
- ¶Departments of Ophthalmology and Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio 44106
| | - John W. Crabb
- From the ‡Cole Eye Institute and
- §Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
- ‖Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106, and
- ¶Departments of Ophthalmology and Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio 44106
| |
Collapse
|
565
|
Integration of ER stress, oxidative stress and the inflammatory response in health and disease. Int J Clin Exp Med 2010; 703:151-62. [PMID: 20369038 DOI: 10.1007/978-1-4419-5635-4_11] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
There has been much effort to define the molecular basis by which pathophysiological stimuli initiate and/or propagate the inflammatory response. Recent research endeavors on stress response from a cellular organelle called the endoplasmic reticulum (ER) shed new light on the understating of the molecular basis of the inflammatory response and its interaction with other intracellular stress signaling pathways. As a protein folding compartment and dynamic calcium store, the ER plays major roles in sensing cellular stress and mediating highly-specific signaling pathways termed Unfolded Protein Response (UPR). The UPR signaling emanating from the ER has been identified as one of the avenues leading to the inflammatory response. The integration of ER stress, oxidative stress, and the inflammatory response is critical to the pathogenesis of a variety of diseases. In this brief review, we discuss some representative evidence for the integration of ER stress, oxidative stress, and inflammation in health and disease.
Collapse
|